These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 20147856)
1. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer. Satouchi M; Kotani Y; Katakami N; Shimada T; Urata Y; Yoshimura S; Funada Y; Hata A; Ando M; Negoro S J Thorac Oncol; 2010 May; 5(5):696-701. PubMed ID: 20147856 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G; Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571 [TBL] [Abstract][Full Text] [Related]
3. Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study. Takiguchi Y; Seto T; Ichinose Y; Nogami N; Shinkai T; Okamoto H; Minato K; Seki N; Eguchi K; Kishi K; Nishikawa M; Watanabe K J Thorac Oncol; 2011 Jan; 6(1):156-60. PubMed ID: 21107293 [TBL] [Abstract][Full Text] [Related]
4. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer. Stinchcombe TE; Peterman AH; Lee CB; Moore DT; Beaumont JL; Bradford DS; Bakri K; Taylor M; Crane JM; Schwartz G; Hensing TA; McElroy E; Niell HB; Harper HD; Pal S; Socinski MA J Thorac Oncol; 2011 Sep; 6(9):1569-77. PubMed ID: 21716146 [TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer. Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S; Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605 [TBL] [Abstract][Full Text] [Related]
9. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Mok TS; Lam KC; Lee C; Zhang L; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Zee B Oncology; 2005; 68(4-6):485-92. PubMed ID: 16020979 [TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793 [TBL] [Abstract][Full Text] [Related]
11. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221 [TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)]. Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656 [TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160 [TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155 [TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Nokihara H; Lu S; Mok TSK; Nakagawa K; Yamamoto N; Shi YK; Zhang L; Soo RA; Yang JC; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim WT; Morita S; Tamura T Ann Oncol; 2017 Nov; 28(11):2698-2706. PubMed ID: 29045553 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673 [TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. Laskin JJ; Nicholas G; Lee C; Gitlitz B; Vincent M; Cormier Y; Stephenson J; Ung Y; Sanborn R; Pressnail B; Nugent F; Nemunaitis J; Gleave ME; Murray N; Hao D J Thorac Oncol; 2012 Mar; 7(3):579-86. PubMed ID: 22198426 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Belani CP; Dakhil S; Waterhouse DM; Desch CE; Rooney DK; Clark RH; Monberg MJ; Ye Z; Obasaju CK Ann Oncol; 2007 Jan; 18(1):110-115. PubMed ID: 17043094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]